通过控制癌前病变拦阻癌症

ncer risk for carriers of defective BRCA genes.

Cancer interception, via the systematic targeting of premalignancy, offers a chance to confront an even greater range of cancer types. Already, treatment of premalignant conditions has proven effective in reducing the risk of developing many full-blown cancers. Drugs that treat precancerous conditions of blood-forming cells can limit progression to leukemia or multiple myeloma. At solid organ sites, precancerous lesions tend to resemble cancers in many ways. Although they are incapable of growing invasively, these lesions can give rise to invasive cancers. For this reason, if they can be removed, the risk for life-threatening cancer is often reduced. Removal of polyps from the colon to prevent colorectal cancer is an example of this approach.

To best tackle premalignancy, research on the gene defects acquired by precancerous cells must be intensified. Just as cataloguing gene defects in established cancers has led to precision treatments guided by the specific gene alterations present in individual cancer cases, taking inventory of gene alterations in premalignant lesions could lead to similar benefits. In addition, the spectacular responses of some metastatic cancers to immunotherapy highlight the need for deeper studies of how the immune system recognizes and responds to premalignancy. Perhaps new immunotherapy approaches could reduce or eliminate precancerous lesions and other precancerous conditions.

Ramping up research on premalignancy offers the best response to a challenge issued almost a decade ago by Elizabeth Blackburn, PhD, a Nobel laureate and Past President of the American Association for Cancer Research, which publishes Cancer Today: “Although treating or even curing cancer is often, understandably, at the forefront of people’s minds, cancer will never be brought under control unless the other side of the equation is addressed: intercepting, or preventing, it.”

William G. Nelson, MD, PhD, is the editor-in-chief of Cancer Today, the quarterly magazine for cancer patients, survivors, and caregivers published by the American Association for Cancer Research. Nelson is the Marion I. Knott professor of oncology and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. You can read his complete column in the winter 2020/2021 issue of Cancer Today.

公开发表于AACR官方博客《Cancer Research Catalyst 》

扫码即可主办单位越来越多预约用药机但会看这里！

8种抗癌从药厂招募HER2+、ER/PR+以及三阴癌症病人

2020年社会保险附录越来越从新，类似物药暴发的这些变化你都知道吗？

癌症类似物耐药后该怎么办？至少有4种提案可以挽救

6种类似物从药厂招募病人！癌症、癌症、癌症等癌种全可预约申特地

招募更早非小肝细胞癌症病人丨ROS1类似物药

类似物抗病毒从药厂实是力，5大癌种迎来从新突破！

CDK4/6治疗法||招募||HR+/HR-20世纪癌症

招募癌症病人||PD-1联合类似物治疗法

招募EGFR突变非小肝细胞癌症病人|类似物治疗法

———————END———————

瞩目关注收藏交友转发、点击左下角在看。

如需尽力特地facebook！

。

咽喉肿痛有异物感
感冒上火嗓子疼吃什么
如何调理儿童脾胃虚弱
性心理
女性生理安全期
维b的作用
尿混浊
胎寒